







an Open Access Journal by MDPI

Novel Approaches to Cancer Immuno-Therapeutics

Guest Editors:

Dr. Youg Raj Thaker

School of Life Sciences, University of Essex, Colchester, UK

Dr. Frank Schildberg

Department for Orthopedics and Trauma Surgery, University Hospital Bonn, 53127 Bonn, Germany

Deadline for manuscript submissions:

closed (31 October 2021)

Message from the Guest Editors

Dear Colleagues,

Cancer immunotherapy uses a person's immune system to invokes its in-built potential to kill cancer cells. Over the checkpoint blockade immunotherapy revolutionized the field of cancer. Several checkpoint blockade inhibitors to molecules such (programmed cell death 1) and CTLA-4 (cytotoxic Tlymphocyte-associated protein 4) have been approved by the FDA for the treatment of various cancer types. However, many of these treatments have still not reached to the majority of patients, and not all types of cancers respond Additionally, them. some patients immunotherapy-associated adverse events. All of this means that there is still a lot of room for improvement when it comes to these therapies, but also huge potential.

This Special Issue is focused on recent novel developments in cancer immunotherapeutics, development of new approaches to identify novel targets of immunotherapy, and recent developments in combinatorial approaches.













an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Jukka Finne

Research Programme in Molecular and Integrative Biosciences, Faculty of Biological and Environmental Sciences, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland

Prof. Dr. Andrés Moya

Integrative Systems Biology Institute, University of Valencia and CSIC, 46980 Valencia, Spain

Message from the Editorial Board

A major strength of biological science is the diversity of approaches that biological scientists apply to their research problems. *Biology* reflects this diversity and brings together studies employing the varied experimental and theoretical approaches that are fueling biological discovery. *Biology*, the journal, is a fully peer-reviewed publication with a rapid and economical route to open access publication and is listed on PubMed. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Biology*) / CiteScore - Q1 (*General Agricultural and Biological Sciences*)

Contact Us